Abstract:Parkinson's disease (PD) is a syndrome with deterioration of neurons, with its onset starting in the '20s, known as the young beginning of Parkinson's to the late inception of the ailment in the 60s. The majority of the environmental risk associated with PD is age. The pathophysiology of PD is related to the accretion of synuclein alpha (SNCA) protein leading to toxicity. This toxicity further leads to a depletion in dopamine levels, creating both motor and non-motor symptoms. PD is the combination of genetic and environmental risk factors. Linkage and association studies provided data on autosomal dominant and recessive genes linked to PD. Current treatment regimes involve using levodopa, catechol-O-methyl transferase inhibitors, anticholinergics, and monoamine oxidase B (MAO-B) inhibitors. Genetic treatment is done by identifying possible targets. Gene therapy includes silencing, replacing, or correcting the flawed gene with a good gene. This therapy has the advantage of eliminating significant PD symptoms with fewer to no adverse effects than conventional treatment. These targets are organized into disease-modifying or non-disease modifying. The distinction between these two is that disease-modifying treatment stops the degeneration of neurons, while non-disease modifying treatment involves dopaminergic enzyme expression. In non-modifying targets, aromatic L-amino acid decarboxylase (AADC) therapy is used but not as a standalone, so the presentation of AADC, tyrosine hydroxylase (TH), and GTP cyclohydrolase 1 (GCH) is done together as a tricistronic system. With these developments, a drug named prosavin is under clinical phase 1 trial. Disease-modifying targets involve glial cell-derived neurotrophic factor (GDNF). Direct GDNF delivery reduces PD symptoms. This GDNF infusion technique works with a tetracycline-controlled transactivator. Gene therapy introduction into the treatment of PD would be beneficial as there would be lesser adverse effects seen as linked with conventional treatment involving levodopa, MAO-B inhibitors, and anticholinergics, among a few. This article discusses the genetic basis and genetic model of therapy for PD.

Advances in targeted therapies for Parkinson's disease

An Update on Potential Therapeutic Strategies for Parkinson’s Disease Based on Pathogenic Mechanisms

Advances in the anti-Parkinson's disease drugs

New advance for disease modification therapy in Parkinson's disease

Emerging targets and new small molecule therapies in Parkinson’s disease treatment

Advances in pharmacogenetics of anti-Parkinson's drugs treatment

Targeting the Pathogenesis and Boosting the Therapeutic Efficacy of Parkinson's Disease by Advanced Nanoparticles

Parkinson disease therapy: current strategies and future research priorities

Recent Advances in Dopaminergic Strategies for the Treatment of Parkinson’s Disease

Small Molecules in Parkinson's Disease Therapy: From Dopamine Pathways to New Emerging Targets

Recent advances in novel mutation genes of Parkinson's disease

Pharmacogenomics—a New Frontier for Individualized Treatment of Parkinson’s Disease

Enhancements in Parkinson's Disease Management: Leveraging Levodopa Optimization and Surgical Breakthroughs

Old and new challenges in Parkinson's disease therapeutics

A Review on Therapeutic Strategies against Parkinson’s Disease: Current Trends and Future Perspectives

GBA1-and LRRK2-directed treatments: The way forward

Parkinson's disease: From genetics to molecular dysfunction and targeted therapeutic approaches

A Review of Genetic and Gene Therapy for Parkinson’s Disease

Current Experimental Studies of Gene Therapy in Parkinson's Disease.

An update on advanced therapies for Parkinson's disease: From gene therapy to neuromodulation

Targeting autophagy using small-molecule compounds to improve potential therapy of Parkinson's disease